Trial Profile
A Phase I/II Trial of Ruxolitinib in Chronic Lymphocytic Leukemia Patients at Risk for Progression on Ibrutinib
Status:
Not yet recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Ruxolitinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 08 Mar 2017 Planned initiation date changed from 1 Dec 2016 to 31 Mar 2017.
- 29 Sep 2016 New trial record